Methotrexate Hepatotoxicity in Psoriatics: Report of 104 Patients from Nova Scotia, with Analysis of Risks from Obesity, Diabetes and Alcohol Consumption During Long Term Follow-Up | Zendy

D. A. Malatjalian | Zendy; J M Ross | Zendy; Williams Cn | Zendy; SJ Colwell | Zendy; B. J. Eastwood | Zendy

Open Access

Methotrexate Hepatotoxicity in Psoriatics: Report of 104 Patients from Nova Scotia, with Analysis of Risks from Obesity, Diabetes and Alcohol Consumption During Long Term Follow-Up

Author(s) -

D. A. Malatjalian,

J M Ross,

Williams Cn,

SJ Colwell,

B. J. Eastwood

Publication year - 1996

Publication title -

canadian journal of gastroenterology and hepatology

Language(s) - English

Resource type - Journals

eISSN - 2291-2797

pISSN - 2291-2789

DOI - 10.1155/1996/213596

Subject(s) - medicine , cirrhosis , discontinuation , diabetes mellitus , gastroenterology , psoriasis , methotrexate , incidence (geometry) , obesity , surgery , dermatology , endocrinology , physics , optics

Methotrexate (MTX) hepatotoxicity in psoriatic patients is well recognized, but there are discrepancies in the reported incidence and associated risk factors. This retrospective study describes 104 Nova Scotian patients with psoriasis seen between 1979 and 1990. Patients received MTX over one to 11 years (mean 3.38), with baseline and annual follow-up liver biopsies. Clinical data were obtained by chart review. Statistical analysis evaluated the risks associated with obesity, diabetes, alcohol consumption and duration of therapy, with the histological grade of liver biopsies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research